GI practice valuation rests on EBITDA multiples that reflect procedure volume, ASC ownership, provider depth, and payer mix strength. Start by calculating true EBITDA: take total net collections from all sources (procedures, evaluation/management visits, ancillary services, facility fees if ASC-owned), subtract provider compensation (salaries, bonuses, benefits for GIs and APPs), subtract clinical staff payroll (nurses, medical assistants, front desk), subtract facility costs (rent/mortgage, utilities, equipment maintenance, EMR costs), subtract supplies and equipment, subtract insurance and malpractice, then subtract administrative and overhead. Your resulting EBITDA is the valuation baseline.

The 7x-14x EBITDA range reflects acquisition activity by health systems, consolidators, and PE firms. A GI practice generating $400K EBITDA with 2,500 procedures annually, strong ASC partnership, and 2 providers trades closer to 10x ($4M) than 7x ($2.8M). The same practice with solo provider and hospital-only procedural setting trades closer to 7.5x ($3M). ASC ownership alone is worth $1M-2M in valuation uplift because it dramatically improves EBITDA through facility fee capture.

Procedure volume is the primary revenue anchor. Calculate your annual procedure count by type: (1) screening colonoscopies, (2) therapeutic procedures (polypectomy, stent, bleeding control), (3) EGDs, (4) advanced procedures (endoscopic ultrasound, cholangiography). Each screening colonoscopy generates $400-550 net revenue (colonoscopy fee + facility fee if ASC-owned); therapeutic procedures generate $600-900+ because they include additional procedure codes and higher reimbursement. A practice performing 2,500 total procedures with 45% therapeutic case mix generates roughly $1.2M net revenue from procedures alone (1,375 screening at $475 average = $652K; 1,125 therapeutic at $750 average = $844K). Add E&M visit revenue (5-10 new patient visits, 20-30 follow-up visits per week) and ancillary revenue (pathology, infusion, CCM), and total gross revenue likely reaches $1.5M-2M.

ASC ownership is the primary valuation multiplier. Practices in hospital outpatient departments keep roughly 50-60% of facility fees with hospitals capturing 40-50%. An ASC-partnered practice keeps 70-80% of facility fees, or if fully owned, keeps 100% plus makes equity returns on ASC operations. A 2,500 procedure practice with facility fee averaging $200 per procedure generates $500K facility revenue annually. In hospital setting, practice realizes $250-300K; in partner-ASC, practice realizes $350-400K; in fully-owned ASC, practice realizes $500K plus equity upside. This $150-250K annual margin difference is worth $1.5M-2.5M in EBITDA multiple valuation alone.

Provider depth affects valuation nonlinearly. A solo GI practice valued at 7x-8x EBITDA faces key-person risk; if the doctor leaves, the practice loses 80%+ value. A 2-provider practice valued at 9.5x-11x EBITDA has operational continuity; if one provider departs, the remaining provider can generate 60-70% historical revenue while recruiting replacement. A 3-provider practice valued at 11x-13x EBITDA has significant depth; one provider departure triggers minimal revenue loss and recruitment continues methodically. Each additional provider-equivalent in capacity (whether GI or capable APP) adds $200-300K incremental EBITDA and supports 0.5x-1x multiple uplift.

Ancillary services add hidden valuation. A practice with 300+ active IBD patients offering on-site infusion therapy generates $300K-500K annual infusion revenue at 70%+ margins, adding $210-350K EBITDA. Pathology revenue from own lab (if managed in-house) captures 15-20% markup on specimen handling and interpretation. Anesthesia partnerships generate 10-15% service fee on deeper sedation procedures. These ancillary streams compound to $100-300K additional EBITDA and are valued at the same multiple as primary business EBITDA.

Payer mix optimization is a non-obvious valuation driver. A practice with 65% Medicare + Medicare Advantage, 25% commercial, 10% HMO generates higher net collection per procedure than 45% Medicare, 35% HMO, 20% commercial at same gross charges. Calculate net per procedure: if gross charges per procedure are $1,200 but net collected is $600 (50% collection rate), you're underperforming the market. Benchmark against regional peers: Medicare net should be 80-85% of allowed amount, Medicare Advantage 85-95%, commercial 75-85% (depending on contracts), HMO 60-75%. Practices with favorable payer mix and strong collections rate net $750-900 per procedure; weaker practices net $500-650. This $150-300 difference per procedure on 2,500 annual procedures is $375K-750K annual revenue difference, supporting 1-2x multiple variance.

Chronic care management (CCM) and remote patient monitoring codes create recurring revenue. An IBD-focused practice managing 300 active IBD patients with CCM billing (requires 20+ minutes monthly care coordination per patient) generates $100-200K annually in dedicated CCM revenue beyond procedures. These codes are non-procedural, high-margin (80%+), and create patient stickiness. Health systems specifically value practices with strong CCM billing because it improves quality metrics (disease activity monitoring) and supports value-based reimbursement strategies.

Buyers actively acquiring GI practices include large health systems (UnitedHealth/Optum, Cigna/Evernorth, Elevance Health), private equity platforms (Aveanna, BrightSpring, Encompass Health), and specialized PE firms focused on healthcare services. Their acquisition targets are practices with $400K+ EBITDA, 2,000+ procedures annually, and multiple providers. Health systems bid 8x-11x EBITDA and are willing to pay premium for ASC-owned practices. PE buyers bid 10x-14x EBITDA because they apply operational and acquisition rollup strategies.

Timing matters for GI practices. Most practices show stronger volume and profitability in Q1 and Q4 (post-holiday preventive care surge and pre-holiday deferrals). Close valuations in Q2-Q3 using annualized full-year data so seasonal variation doesn't distort metrics. A practice showing strong January-March numbers might appear overstated.

Regulatory compliance is table stakes. Verify joint commission accreditation if ASC-owned, state licensing for all providers, proper credentialing with major payers, and clean compliance record (no excluded parties list issues, no fraud/abuse investigations). Document all ASC ownership structures, revenue-share agreements, and facility fee distributions. Regulatory issues trigger 20-50% discount requests.